Search results for "Forced"

showing 10 items of 500 documents

Alternative ways of expressing forced expiratory volume in the first second and long-term mortality in elderly patients with asthma

2013

Abstract Background Clinical and epidemiologic evidence on asthma in the elderly is scant. There is evidence that forced expiratory volume in the first second (FEV 1 ), a commonly used indicator of overall pulmonary function, might not be an independent predictor of 5-year mortality in elderly patients with asthma. Objective To investigate the association between FEV 1 expressed using 3 alternative methods and 5-, 10-, and 15-year mortality in a population of elderly patients with asthma. Methods Participants in the Salute Respiratoria nell' Anziano study were included. Asthma was diagnosed at baseline according to spirometric and clinical data. Vital status at 15 years was assessed using d…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPercentileImmunologyPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary function testingForced Expiratory VolumeInternal medicineHumansImmunology and AllergyMedicineeducationLungAgedAsthmaAged 80 and overeducation.field_of_studybusiness.industryHazard ratioConfoundinglung functionasthmaPrognosismedicine.diseaseConfidence intervalRespiratory Function Testsrespiratory tract diseasesSpirometryPhysical therapyFemaleLong term mortalitybusiness
researchProduct

Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study

2019

Abstract Background The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants. Methods The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT a…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationWalk TestComorbiditySeverity of Illness IndexPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineForced Expiratory VolumeInternal medicinePrevalencemedicineHumansEurope Eastern030212 general & internal medicineBulgariaTrial registrationeducationDepression (differential diagnoses)AgedHungaryeducation.field_of_studyCOPDDepressionbusiness.industryMiddle AgedExercise capacitymedicine.diseaseRespiratory Function Tests3. Good healthEastern europeanCross-Sectional Studies030228 respiratory systemPhysical EnduranceCopd assessment testFemaleObservational studySymptom AssessmentbusinessRespiratory Medicine
researchProduct

Coercion in a locked psychiatric ward: Perspectives of patients and staff

2013

Background: In spite of a national strategy for reducing coercion in the mental health services, Norway still has a high rate of involuntary treatment compared to other European countries. It is therefore crucial to study various parties involved in involuntary treatment in order to reduce coercion. Research question: How do patients and staff in a Norwegian locked psychiatric ward experience coercion? Research design: Participant observation and interviews. Participants: A total of 12 patients and 22 employees participated in this study. Ethical considerations: This study is accepted by the National Committee for Medical Health Research Ethics. Findings: The participants experienced coerci…

MaleResearch designcoercionmedicine.medical_specialtyAttitude of Health Personnelmedia_common.quotation_subjectvulnerabilityPsychiatric Department HospitalCoercionNorwegianParticipant observationInterviews as TopicVDP::Medical disciplines: 700::Health sciences: 800::Nursing science: 808DignityNursingMedical Staff HospitalmedicineHumansPsychiatrymedia_commonforced treatmentInpatientsNorwayseclusionlocked psychiatric wardMental healthlanguage.human_languageIssues ethics and legal aspectsInvoluntary treatmentlanguageethical sensitivityFemaleSeclusionPsychologyexperiences of staff and patients
researchProduct

Restrictive pulmonary dysfunction at spirometry and mortality in the elderly

2008

SummaryObjectivesTo evaluate the association between pulmonary restriction and mortality in the elderly, taking into account potential confounders not considered in the past (disability, cognitive dysfunction, diabetes, and visceral obesity).DesignLongitudinal study.SettingCommunity-based.ParticipantsTwelve hundred sixty-five patients (51.9% men) aged 65–97 years old from the Salute Respiratoria nell'Anziano (SaRA) Italian multicentric study.MeasurementsParticipants were divided in 4 groups: normal spirometry (NS): FEV1/FVC≥70%, FVC≥80% of predicted; restrictive ventilatory pattern (RVP): FEV1/FVC≥70%, FVC<80%; obstructive ventilatory pattern (OVP): FEV1/FVC<70%, FVC≥80%, and mixed ventilat…

MaleRiskSpirometryPulmonary and Respiratory MedicineLongitudinal studymedicine.medical_specialtyWaistVital CapacitySettore MED/10 - Malattie Dell'Apparato RespiratorioelderlyLung restrictionPulmonary function testingPulmonary Disease Chronic ObstructiveForced Expiratory VolumeInternal medicineEpidemiologymedicineHumansLung Diseases ObstructiveMortalityGeriatric AssessmentLungStrokeDepression (differential diagnoses)Pulmonary function testsAgedProportional Hazards ModelsAged 80 and overmedicine.diagnostic_testProportional hazards modelbusiness.industryLongitudinal studiesPrognosismedicine.diseaseHealth SurveysItalySpirometryPhysical therapyFemalebusinessFollow-Up StudiesRespiratory Medicine
researchProduct

Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma

2017

Abstract Background Bronchial thermoplasty (BT) is a non-pharmacological intervention for severe asthma whose mechanism of action is not completely explained by a reduction of airway smooth muscle (ASM). In this study we analyzed the effect of BT on nerve fibers and inflammatory components in the bronchial mucosa at 1 year. Methods Endobronchial biopsies were obtained from 12 subjects (mean age 47 ± 11.3 years, 50% male) with severe asthma. Biopsies were performed at baseline (T0) and after 1 (T1), 2 (T2) and 12 (T12) months post-BT, and studied with immunocytochemistry and microscopy methods. Clinical data including Asthma Quality of Life Questionnaire (AQLQ) and Asthma Control Questionnai…

MaleSevere asthmaBronchial biopsieBiopsymedicine.medical_treatmentVital CapacityGastroenterologyBronchial thermoplasty0302 clinical medicineBronchoscopyQuality of lifeForced Expiratory VolumeSubmucosa030212 general & internal medicinemedicine.diagnostic_testCD68Middle AgedNerve fiberAblationImmunohistochemistryResidual VolumeTreatment Outcomemedicine.anatomical_structureAsthma Control QuestionnaireFemaleResearch ArticleAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyBronchiBronchial biopsiesNerve fibersRespiratory MucosaSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicineBronchoscopymedicineHumansAgedAsthmalcsh:RC705-779Bronchial thermoplastybusiness.industryTotal Lung Capacitylcsh:Diseases of the respiratory systemmedicine.diseaseAsthmarespiratory tract diseases030228 respiratory systembusinessBMC Pulmonary Medicine
researchProduct

Assessing biomarkers in a real-world severe asthma study (ARIETTA)

2016

AbstractThe prognostic value of asthma biomarkers in routine clinical practice is not fully understood. ARIETTA (NCT02537691) is an ongoing, prospective, longitudinal, international, multicentre real-world study designed to assess the relationship between asthma biomarkers and disease-related health outcomes. The trial aims to enrol and follow for 52 weeks approximately 1200 severe asthma patients from approximately 160 sites in more than 20 countries. Severe asthmatics, treated with daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 second controller medication are to be included. In this real-world study, patients will be treated according to the…

MaleSevere asthmaCardiac & Cardiovascular SystemsExacerbationAIRWAY INFLAMMATIONRespiratory SystemEosinophilSeverity of Illness Indexlaw.inventionDOUBLE-BLIND0302 clinical medicineQuality of lifeRandomized controlled trialAdrenal Cortex HormoneslawForced Expiratory VolumeProspective Studies030212 general & internal medicineProspective cohort studyFluticasoneEPITHELIAL-CELLSExacerbationRANDOMIZED CONTROLLED-TRIALPrognosis3. Good healthTO-SEVERE ASTHMAFemaleLife Sciences & Biomedicinemedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyPHENOTYPESNitric Oxide1102 Cardiovascular Medicine And HaematologyFluticasone propionate03 medical and health sciencesPredictive Value of TestsAdministration InhalationSeverity of illnessmedicineHumansNITRIC-OXIDE SYNTHASEIntensive care medicineCOMBINATIONAsthmaScience & Technologybusiness.industryPULMONARY-FUNCTION1103 Clinical SciencesBiomarkerImmunoglobulin Emedicine.diseaseAsthmarespiratory tract diseasesEosinophilsBiomarker; Eosinophil; Exacerbation; Periostin; Severe asthma; Pulmonary and Respiratory MedicinePeriostin030228 respiratory systemQuality of LifeCardiovascular System & CardiologyFluticasonebusinessCell Adhesion MoleculesBiomarkersRespiratory Medicine
researchProduct

Factors reducing omalizumab response in severe asthma

2018

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. O…

MaleSevere asthmaDrug ResistanceComorbidityOmalizumabOmalizumabAdrenal Cortex HormoneComorbidities0302 clinical medicineRetrospective StudieAdrenal Cortex HormonesRisk FactorsForced Expiratory VolumeAge FactorNasal polypsAnti-Asthmatic Agents030212 general & internal medicineMultivariate AnalysiSmokingAge FactorsReal-lifeMiddle AgedTreatment OutcomeItalyFemaleComorbiditieHumanmedicine.drugAdultage; comorbidities; obesity; omalizumab; real-life; severe asthma; therapeutic response; internal medicinemedicine.medical_specialtyLogistic ModelTherapeutic responseSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric Oxide03 medical and health sciencesFEV1/FVC ratioNasal PolypsAgeInternal medicineInternal MedicinemedicineAnti-Asthmatic AgentHumansObesityRisk factorRetrospective StudiesAsthmabusiness.industryRisk Factormedicine.diseaseComorbidityAsthmarespiratory tract diseasesLogistic Models030228 respiratory systemConcomitantMultivariate AnalysisExhaled nitric oxideNasal PolypAge; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic responsebusinessEuropean Journal of Internal Medicine
researchProduct

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience

2016

Background This retrospective study aimed at evaluating long-term effects of Omalizumab in elderly asthmatics in a real-life setting. Methods 105 consecutive severe asthmatics (GINA step 4–5; mean FEV1% predicted:66 ± 15.7) treated with Omalizumab for at least 1 year (treatment mean duration 35.1 ± 21.7 months) were divided into 3 groups according to their age at Omalizumab treatment onset: 18–39, 40–64 and ≥ 65 years. Results Comorbidities, number of overweight/obese subjects and patients with late-onset asthma were more frequent among older people. A similar reduction of inhaled corticosteroids dosage and SABA on-demand therapy was observed in all groups during Omalizumab treatment; a sim…

MaleSevere asthmaPediatricsComorbidityOmalizumabOmalizumabOverweightImmunoglobulin ESeverity of Illness IndexElderly0302 clinical medicineAdrenal Cortex HormonesForced Expiratory VolumeAge effectAnti-Asthmatic Agentsasthma allergy elderly omalizumab030212 general & internal medicineYoung adultbiologyReal-lifeAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeItalyFemalemedicine.symptommedicine.drugAdultPulmonary and Respiratory Medicineage effect; elderly; omalizumab; real-life; severe asthmamedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciencesAge effect; Elderly; Omalizumab; Real-life; Severe asthma; Pulmonary and Respiratory MedicineAdministration InhalationSeverity of illnessmedicineHumansAgedRetrospective StudiesAsthmabusiness.industryRetrospective cohort studyImmunoglobulin Easthmaallergymedicine.diseaseComorbidity030228 respiratory systembiology.proteinbusinessRespiratory Medicine
researchProduct

Global Lung Function Initiative 2012 reference values for spirometry in South Italian children

2017

Rationale Despite the widespread use of the Global Lung Function Initiative (GLI) 2012 reference values, there is still the need of testing their applicability in local areas. Objectives The aims of this study are to evaluate applicability of GLI reference equations in a large population-based sample of normal schoolchildren from Sicily, and to compare GLI and previous prediction equations in terms of spirometry test interpretation. Methods GLI equations were evaluated in 1243 normal schoolchildren, 49% males, aged 7–16 years, height 116–187 cm. Normality assumptions for the GLI z-scores (FEV1, FVC, FEV1/FVC) were tested, and bootstrap confidence intervals for the mean (0 expected) and …

MaleSpirometryPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyPulmonary functionAdolescentmedia_common.quotation_subjectVital CapacityStandard scoreWhite PeoplePulmonary function testing03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineReference ValuesForced Expiratory VolumemedicineHumans030212 general & internal medicineChildLungSicilyNormalityLung functionmedia_commonintegumentary systemmedicine.diagnostic_testbusiness.industryZ-scorerespiratory systemrespiratory tract diseasesAirway ObstructionItaly030228 respiratory systemSpirometryPaediatricReference valuesFemaleBootstrap confidence intervalbusinessReference equationcirculatory and respiratory physiologyDemography
researchProduct

Authors’ response

2012

Claudio Sorino,1,2 Salvatore Battaglia,1 Nicola Scichilone,1 Claudio Pedone,3 Raffaele Antonelli-Incalzi,3 Duane Sherrill,4 Vincenzo Bellia11Biomedical Department of Internal and Specialist Medicine, Section of Pulmonology, University of Palermo, Italy; 2Division of Pulmonology, S Anna Hospital, Como, Italy; 3Chair of Geriatrics, University Campus Bio-Medico, Roma, Italy; 4Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USABackground: The choice between lower limit of normal or fixed value of forced expiratory volume in one second/forced vital capacity ratio (FEV1/FVC) &amp;lt; 0.70 as the criterion for confirming airway obstruction is an open issue. In t…

MaleSpirometryVital capacitymedicine.medical_specialtyLetterCross-sectional studyVital CapacityInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary function testingPulmonary Disease Chronic ObstructiveFEV1/FVC ratioForced Expiratory VolumeInternal medicinemedicineHumansAgedAged 80 and overlcsh:RC705-779COPDmedicine.diagnostic_testbusiness.industryGeneral MedicineHealthy elderlylcsh:Diseases of the respiratory systemAirway obstructionrespiratory systemmedicine.diseaselung function test elderlyRespiratory Function TestsSurgeryrespiratory tract diseasesCross-Sectional StudiesItalyCardiologyFemalebusinesscirculatory and respiratory physiologyInternational Journal of COPD
researchProduct